Clinical pathways can act as a tool to assist oncology practices to promote testing of key biomarkers and subsequent selection of appropriate therapy.
Patterns of Biomarker Testing Rates and Appropriate Use of Targeted Therapy in the First-Line, Metastatic Non–Small Cell Lung Cancer Treatment Setting
Tumor cells collected during the removal of a cancerous bladder may help clinicians better identify high-risk cancers, determine prognosis, refine their use of biomarkers, and provide more personalized care, according to a study published in Scientific Reports.
Serum microRNA-206 may serve as not only a novel diagnostic biomarker for gastric cancer but also as an indicator of prognosis and cancer recurrence.
Richard Schilsky, MD kicked off the Clinical Pathways Congress discussing the relationship between clinical pathways development and emergence of precision medicine.
A non-invasive liquid biopsy may be more effective at detecting clinically relevant mutations in patients with advanced lung cancer than standard biopsies.
The presence of two cellular biomarkers may help to identify patients with rheumatoid arthritis who will not benefit from rituximab.
Researchers have developed a novel centromere and kinetochore gene Expression Score signature, which could lead to a new biomarker for the early stages of cancer development and help patients avoid unnecessary cancer treatments.